Kauffman Michael Form 4 May 21, 2018

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB

3235-0287 Number:

January 31, Expires: 2005

Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940

See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person *

Kauffman Michael

2. Issuer Name and Ticker or Trading Symbol

Karyopharm Therapeutics Inc.

[KPTI]

(Last) (First) (Middle)

3. Date of Earliest Transaction

05/18/2018

5. Relationship of Reporting Person(s) to

Issuer

(Check all applicable)

(Month/Day/Year)

X Director X_ Officer (give title

10% Owner Other (specify

below) Chief Executive Officer

C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS **AVENUE**

(Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

NEWTON, MA 02459

(City)	(State)	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securit onor Dispos (Instr. 3,	sed of	` ′	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	05/18/2018		M <u>(1)</u>	10,000	A	\$ 0.264	522,143	D			
Common Stock	05/18/2018		S(1)	10,000	D	\$ 19.387 (2)	512,143	D			
Common Stock							713,510	I	By Spouse		
Common Stock							47,309	I	By GRAT		

Common Stock 47,309 I Spouse's $\frac{1}{6RAT^{(4)}}$

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 0.264	05/18/2018		M <u>(1)</u>	10,000	<u>(5)</u>	12/13/2021	Common Stock	10,000

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

Director 10% Owner Officer Other

Kauffman Michael

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE NEWTON, MA 02459 X

Chief Executive Officer

Signatures

/s/ Christopher B. Primiano, Attorney-in-Fact for Michael G. Kauffman

05/21/2018

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

Reporting Owners 2

Edgar Filing: Kauffman Michael - Form 4

- Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from \$19.11 to \$19.54,
- (2) inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- (3) These shares are held by the Michael G. Kauffman 2016 Qualified Annuity Interest Trust.
- (4) These shares are held by the Sharon Shacham 2016 Qualified Annuity Interest Trust.
- (5) This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on June 18, 2013, and the remaining 75% vested in 36 equal monthly installments thereafter.
- (6) This amount has been adjusted to include 7,576 shares underlying this stock option that were inadvertently omitted from the last row of Column 9 of Table II of the reporting person's Form 4 filed on April 20, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.